Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total transaction of $35,140.90. Following the transaction, the director now owns 124,490 shares in the company, valued at approximately $3,444,638.30. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $28.02 on Friday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $28.62. The firm has a market capitalization of $1.32 billion, a PE ratio of -14.52 and a beta of 1.10. The stock’s 50-day simple moving average is $23.92 and its 200-day simple moving average is $22.57.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.17. Sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several large investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at about $256,000. The Manufacturers Life Insurance Company acquired a new stake in Enliven Therapeutics in the second quarter valued at approximately $322,000. Marshall Wace LLP purchased a new stake in shares of Enliven Therapeutics in the second quarter valued at approximately $4,489,000. First Turn Management LLC acquired a new position in shares of Enliven Therapeutics during the 2nd quarter worth approximately $9,657,000. Finally, Nicholas Investment Partners LP purchased a new position in shares of Enliven Therapeutics during the 2nd quarter valued at approximately $1,310,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.